125 results about "Polycystic ovary" patented technology

The present invention belongs to the technical field of plant extracts, and more specifically, relates to the use of a carob extract in a drug for improving glucose metabolism / polycystic ovary syndrome in women. The present invention discloses a pharmaceutical composition for improving glucose metabolism and treating polycystic ovary syndrome in women, the pharmaceutical composition comprising: carob extract, baicalein, cedrol, a bioactive peptide, a biopolysaccharide, and excipients. The composition of the present invention has the effects of lowering blood sugar and blood lipids, improving insulin function, and also has antioxidant and immunity-enhancing effects. By combining the above substances, a synergistic effect is achieved, further enhancing the effect of improving / treating polycystic ovary syndrome in women associated with abnormal glucose metabolism.

The invention provides application of combination of antrodia camphorata polysaccharide and forsythin in preparation of drugs for treating metabolic diseases related to insulin resistance, and belongs to the technical field of biological medicines. The metabolic diseases related to insulin resistance include polycystic ovarian syndrome. Animal experiments find that the combination of the antrodia camphorata polysaccharide and forsythin can significantly reduce serum testosterone and luteinizing hormone levels of a rat with the polycystic ovarian syndrome, improve serum follicular hormone and estradiol levels, and achieve the effect of improving the polycystic ovarian syndrome.

The invention relates to the field of biomarkers, and particularly provides a polycystic ovarian syndrome pregnancy outcome diagnosis marker and application thereof. According to the present invention, the endometrial targeting metabonomics research is adopted to screen the disease-related potential metabolic markers such as N-Acetylaspartic acid, Suberic acid and isoallolithocholic acid, and the three metabolites are subjected to quantitative detection so as to accurately predict the pregnancy outcome of the polycystic ovarian syndrome patient, such that the pregnancy outcome of the polycystic ovarian syndrome patient can be accurately predicted, and the prediction of the pregnancy outcome of the polycystic ovarian syndrome patient can be easily achieved, such that the disease-related potential metabolic markers such as N-Acetylaspartic acid, suberic acid and isoallolithocholic acid can be provided. A new path is provided for early intervention of the disease state to improve the pregnancy outcome, and a new drug target is provided for evaluation of the endometrial function of the polycystic ovarian syndrome.

The invention discloses a preparation method of cryptotanshinone-loaded PDA (Polydopamine) nano drug-loaded particles. The technical scheme adopted by the invention is as follows: the cryptotanshinone is loaded on PDA (Polydopamine) nano particles. Photo-thermal therapy and pharmaceutical chemotherapy are integrated into designed nano-delivery to impart a targeted synergistic effect thereto. In addition, the PDA nanoparticles show photoacoustic imaging capability, and aggregation of the nanoparticles at the ovary part can be monitored in real time. The cryptotanshinone is loaded by utilizing aperture adsorption of PDA and pi-pi conjugation and hydrophobic interaction with the cryptotanshinone, so that a drug delivery system is constructed, the biological solubility and the utilization rate of the cryptotanshinone are improved, a slow release effect is achieved, the application of the cryptotanshinone is widened, and the purpose of treating the polycystic ovarian syndrome is achieved.

The application belongs to the technical field of biomedicine, and particularly relates to a miRNA marker for diagnosing polycystic ovary syndrome and application thereof. The miRNA marker comprises one or a combination of hsa-miR-185-5p and hsa-miR-4433b-3p. The application first uses a plurality of extracellular vesicle (EVs) miRNAs such as hsa-miR-185-5p for diagnosing polycystic ovary syndrome patients, and it is found through verification in real clinical samples collected in the application that the plurality of extracellular vesicle (EVs) miRNAs such as hsa-miR-185-5p have good diagnostic efficiency for diagnosing polycystic ovary syndrome, and have high accuracy, sensitivity and specificity, and can be used for effective diagnosis of polycystic ovary syndrome. The application provides a brand-new thought and strategy for research and development of polycystic ovary syndrome related diagnostic products, and has a wide application prospect and important transformation significance in the technical field of polycystic ovary syndrome diagnosis.

The invention relates to a PCOS metabolic disorder diagnostic kit and application thereof, the PCOS metabolic disorder diagnostic kit is used for detecting unbalance of intestinal and fecal parabacteroides and branched chain amino acid, and if the intestinal and fecal parabacteroides is reduced and the branched chain amino acid is increased at the same time, the PCOS high risk is prompted. The PCOS metabolic disorder diagnostic kit is applied to clinical diagnosis of PCOS patients.

1. The name of the design product: medical detection chip. 2. The use of the design product: the design product is used for non-invasive early screening of polycystic ovary syndrome. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: design 1 perspective view 1. 5. Design 1 is designated as the basic design.

Nutraceutical food supplement for treatment of young women in post-puberty age suffering from polycystic ovary syndrome with symptoms like irregular menstruation cycles, insulin resistant diabetes, infertility, hair loss, acne and weight gain is provided. Formulations having myo-inositol and its D-chiro isomer along with plant proteins, a carbohydrate (inulin) and other plant fibres; along with well-defined proportions of vitamins (A, B1 to 6; B12 and C); several minerals like Ca, Cr, Fe, K, Mg, Mn, Na and Zn and essential amino acids like L-Glutamine, L-Lysine, and L-Taurine are provided.

The present invention relates to a method for diagnosing polycystic ovary syndrome (PCOS) in a subject, comprising the steps of: a) determining the amount or concentration of total FGFBP1 in a sample from the subject; b) determining the amount or concentration of METRNL in the sample from the subject; c) calculating a score for the amounts or concentrations determined in steps a) and b); d) comparing the calculated score with a reference score; and e) diagnosing PCOS in the subject.

The invention belongs to the technical field of medical animal disease model modeling, and particularly discloses a dehydroepiandrosterone-induced mouse polycystic ovarian syndrome model under bisphenol A low-dose exposure, specifically, a preparation method of the model comprises the following steps: continuously injecting a mouse for 21 days according to the injection amount of dehydroepiandrosterone of 6mg / 100g; the method comprises the following steps: carrying out intragastric administration on a mouse by using 10 mg / kg of bisphenol A on the 15th day of injection of dehydroepiandrosterone, and continuously carrying out intragastric administration on the mouse for 7 days to obtain the polycystic ovarian syndrome model of the mouse at the childbearing age. According to the mouse model obtained by DHEA modeling at the early stage of adolescence and BPA exposure modeling at the late stage of adolescence, the disordered mood cycle, obesity and high T level are obviously changed; and the human PCOS disease environment and clinical phenotype can be truly simulated.

The present invention relates to the technical field of molecular diagnosis, and in particular to a use of an HSF2 gene as a diagnostic marker in the preparation of a product for diagnosing polycystic ovary syndrome (PCOS). It is found that the HSF2 gene or an HSF2 protein can be used as a diagnostic marker for PCOS. Compared with a healthy control group, the transcription of HSF2 in the peripheral blood of a PCOS patient and an offspring thereof is significantly elevated, thereby showing a statistical difference. On the basis of sequencing data of the HSF2 gene, an ROC curve for diagnosing PCOS offspring inheritance on the basis of the HSF2 gene is established, and an AUC value is 0.8384. Results show that the HSF2 gene as a diagnostic marker can implement diagnosis or prediction of PCOS, especially diagnosis or prediction of PCOS in an offspring, and has high accuracy, thereby providing a new basis for effective diagnosis of PCOS.

The invention relates to the field of moxibustion treatment, in particular to a moxibustion device for treating polycystic ovarian syndrome, which comprises a box body, a first air inlet, a second air inlet, a combustion component, an ash collecting tray and a metal filter screen, a plurality of first air inlets arranged in a rectangular array are formed in the upper part of the box body; a plurality of groups of second air inlets are formed in the upper part of the box body, and each group of second air inlets are arranged around one first air inlet in a circumferential array manner; the upper portion of the inner side of the box body is fixedly connected with a plurality of combustion assemblies arranged in a rectangular array. The lower part of the box body is in sliding connection with two ash collecting trays, and the two ash collecting trays are arranged in a bilateral symmetry manner; and a metal filter screen is fixedly connected to the inner side of each dust collecting disc. The inclined groove is an annular groove with the high middle and the two low sides, and the inclined groove is arranged to be annular and can guide the trend of moxa stick combustion waste; the moxa smoke is upward, and the particles and the moxa oil are downward under the action of gravity, so that wastes can be collected in a targeted manner, and the influence of the wastes is reduced.

The invention discloses application of clostridium butyricum based on clostridium butyricum with the product number of BNCC337239 in preparation of a medicine or food for treating and / or preventing polycystic ovarian syndrome, and a culture method of the clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum. According to the present invention, the bacterial strain is subjected to anaerobic culture to prepare the bacterial liquid, the intragastric administration frequency is 1-3 times per week at the dosage of 0.1-0.5 mL / 100 g, and the intragastric administration lasts for 3-8 weeks, such that the estrus cycle disorder, the insulin resistance, the blood sex hormone disorder and the ovarian polycystic degeneration of the PCOS rat model can be significantly improved, and the method can be used for preparing the drug for treating the polycystic ovarian syndrome.

The invention discloses a diagnostic marker for polycystic ovarian syndrome, and in particular, the diagnostic marker is 16 (17)-EpDPE. The diagnostic marker provided by the invention can be used for diagnosing the polycystic ovarian syndrome, and has high diagnostic efficiency and wide clinical application prospect.

The invention discloses a medicine for treating polycystic ovarian syndrome and application thereof, which can overcome the defects that in the prior art, western medicine for treating polycystic ovarian syndrome is lack of radical treatment, multi-medicine combined application is realized, and complications exist in operations. According to the medicine for treating the polycystic ovarian syndrome, akebia saponin D is the only active ingredient, and the molecular formula of the akebia saponin D is as follows: # imgabs0 #

The present invention provides the use of UTP6 in the preparation of a product for diagnosing polycystic ovary syndrome, relating to the field of biotechnology. Compared with healthy subjects, UTP6 is differentially expressed in patients with polycystic ovary syndrome. The expression of UTP6 is related to polycystic ovary syndrome, and the diagnosis of polycystic ovary syndrome can be achieved by detecting the expression level of UTP6. In addition, compared with healthy subjects, PIAS4 is differentially expressed in patients with polycystic ovary syndrome. The expression of PIAS4 is related to polycystic ovary syndrome, and the combined use of UTP6 and PIAS4 for the diagnosis of polycystic ovary syndrome has higher detection accuracy.

The invention belongs to the technical field of medicines for treating polycystic ovarian syndrome, and particularly relates to application of astragaloside IV and a compound thereof in preparation of a medicine for treating polycystic ovarian syndrome and the medicine. The compound is prepared from the following raw materials: mannitol, vitamin B3 and vitamin B9, wherein the mass ratio of the mannitol to the vitamin B3 to the vitamin B9 is (0.5-1): (0.5-1): 1; the mass ratio of the astragaloside IV to the compound is 1: (2-4). The mannitol, the vitamin B3 and the vitamin B9 are used for activating a PPAR gamma channel, increasing the relative expression quantity of PPAR gamma and inhibiting proliferation of human ovarian granular cells. And the mannitol, the vitamin B3, the vitamin B9 and the astragaloside IV are mixed for use, so that the effect is optimal.

Compositions and methods of treating or preventing a reproductive disease or condition in a mammalian subject comprising administering to a mammalian subject in need thereof an effective amount of a substantially homogeneous and transformed population of enteric bacterial cells, wherein the administered bacterial cells have been engineered to express bile salt hydrolase (BSH). Compositions and methods for treating or preventing polycystic ovary syndrome (PCOS).

The composition and / or combinations includes diosgenin and at least one other agent selected from vitamin D and α-lactalbumin and its use in the regularization of the menstrual cycle and in the reduction of ovarian cysts, in particular in women affected with polycystic ovarian syndrome (PCOS) phenotype D.

The invention relates to the field of biological medicine, and discloses a protein degradation targeting chimera (PROTAC) compound targeting 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) and medical application of the protein degradation targeting chimera (PROTAC) compound. The compound comprises a structural unit shown as a formula I, X is a 11 beta-HSD1 binding ligand, Y is a connecting chain, Z is an E3 ubiquitin ligase ligand, ubiquitination degradation of 11 beta-HSD1 can be induced, and therefore the function of the compound can be regulated and controlled at the protein level. Different from a traditional small-molecule inhibitor, the degradation agent can significantly reduce expression of 11 beta-HSD1 in cells and improve glucocorticoid signal abnormality, and shows a novel action mode at molecular and cellular levels. In diabetes, obesity, lipid metabolism disorder and related complication models, the compound can reduce blood sugar, improve insulin sensitivity, regulate blood fat and relieve inflammation, and shows a good treatment prospect. The half degradation concentration of a representative compound in vitro is about 1000 nM, and feasible degradation efficiency is achieved. The compound can be synthesized by Click chemistry and other methods, and can be prepared into a pharmaceutical composition for prevention and treatment of type II diabetes, metabolic syndrome, polycystic ovarian syndrome and other diseases, and a new strategy is provided for research and development of related drugs.

This application relates to the field of medical data processing technology and discloses a method and system for screening infertile patients with polycystic ovary syndrome (PCOS). The method includes: acquiring data on the number of antral follicles, anti-Müllerian hormone (AMH) concentration, and ovarian volume from multiple patient monitoring cycles; performing feature extraction and normalization to obtain a set of normalized feature vectors; determining the synchronous relationship between the number of antral follicles and ovarian volume based on the vector set, and identifying signs of asynchronous changes; combining hormone concentrations for joint grouping to obtain the distribution of abnormal indicator clusters and identifying ovarian function stage markers; performing sequence matching based on the stage markers of continuous cycles and historical medical records to generate an ovarian function progression trajectory curve; extracting inflection point features from the curve and performing causal association rule mining to construct a logical chain between abnormal indicators and clinical outcomes; and determining conditions layer by layer according to the logical chain to output the final screening results. This application improves the accuracy of screening infertile patients with PCOS.

A polypeptide that is active against each of a GIP, a GLP-1, and a glucagon receptor is provided. The polypeptides have structural features that result in each of the receptors having activity and extended action time. Also provided are methods for treating diseases and / or conditions such as obesity, long term weight management, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, chronic kidney disease (CKD), osteoarthritis (OA), obesity-associated sleep apnea (OSA), and polycystic ovarian syndrome (PCOS).

Materials and methods of treating a patient with type 2 diabetes mellitus, metabolic syndrome, obesity, infertility, high blood pressure, hyperthyroidism, and hypothyroidism, hyperlipidaemia, osteoporosis, osteoarthritis, hypoadrenalism, polycystic ovary syndrome, or Parkinson's disease comprising administering a therapeutically effective amount of ex vivo cultured activated peripheral blood mononuclear cells (PBMCs) to the patient. The ex vivo cultured activated cells are activated and cultured in a presence of a cytokine and may be autologous or allogeneic relative to the patient.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition, preparation, preparation method, and application for treating polycystic ovary syndrome (PCOS). The traditional Chinese medicine composition for treating PCOS comprises the following raw materials in parts by weight: 10-15 parts of Cuscuta chinensis, 10-15 parts of Lycium barbarum, 10-20 parts of Taxillus chinensis, 10-15 parts of Angelica sinensis, 10-15 parts of Achyranthes bidentata, 10-15 parts of Ligusticum chuanxiong, 10-15 parts of Alisma plantago-aquatica, 10-15 parts of Nelumbo nucifera leaf, 10-15 parts of Gynostemma pentaphyllum, 10-20 parts of Salvia miltiorrhiza, 5-10 parts of Euonymus alatus, 5-10 parts of Coptis chinensis, and 5-10 parts of Glycyrrhiza uralensis. Its core treatment principle is to tonify the kidney and spleen, promote blood circulation, and resolve phlegm, and it is used to treat PCOS.

Disclosed are methods of treating polycystic ovary syndrome (PCOS) comprising administering to the individual a composition comprising an effective amount of Mazdutide or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating polycystic ovarian syndrome as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from Chinese yam, semen cuscutae, pulp of dogwood fruit, radix glehniae, radix scrophulariae, lily, rhizoma polygonati, tortoise shell, cistanche deserticola, lotus seed and raspberry, has the effects of tonifying kidney and replenishing essence, nourishing yin and blood, replenishing qi and tonifying spleen, and benefiting uterus and accommodating fetus, and is mainly used for treating the polycystic ovarian syndrome. Research results show that the traditional Chinese medicine composition can significantly improve the sex hormone level of a patient with the polycystic ovarian syndrome, increase the endometrial thickness, improve the ovarian function and improve the endometrial receptivity, the ovulation rate and the pregnancy rate. Therefore, the traditional Chinese medicine composition has important clinical significance and wide market application prospects.

This invention relates to the field of biomedical technology and discloses a biomarker for diagnosing polycystic ovary syndrome (PCOS) and its application. The diagnostic biomarker is circSPECC1(4), which is formed by reverse splicing and circularization of the fourth exon of the SPECCC1 gene. It has a length of 1580 nt and possesses a closed circular RNA structure. circSPECC1(4) is specifically highly expressed in ovarian granulosa cells of PCOS patients, and there is no significant difference in the mRNA expression level of its parent gene SPECCC1. circSPECC1(4) possesses RNase R nuclease resistance stability and is mainly located in the cytoplasm. Knocking down the expression of circSPECC1(4) can significantly promote apoptosis of ovarian granulosa cells and arrest the ovarian granulosa cell cycle at the G0 / G1 phase. This invention clearly demonstrates that circSPECC1(4) can serve as a specific diagnostic biomarker for PCOS, fully verifying the structural characteristics, expression specificity, and pathological regulatory function of this circular RNA, filling the gap in the existing field of PCOS diagnosis which lacks highly specific and stable molecular diagnostic targets.

MACHINE LEARNING BASED POLYCYSTIC OVARY SYNDROME PREDICTING DEVICE

The invention belongs to the field of molecular biology and reproductive medicine, and particularly relates to an SNP marker for risk prediction of polycystic ovarian syndrome and application of the SNP marker. According to the invention, through large-scale cross-racial GWAS research, 94 independent gene loci are accurately locked from massive samples in the global range, and 73 gene loci are newly found and comprise 250 genetic variation sites (SNP). A PRS model constructed and optimized based on the loci can more stably, economically and accurately predict PCOS risks in an earlier stage, accurately distinguish PCOS high-risk individuals from PCOS low-risk individuals, facilitate layered prevention and control and save medical resources, in addition, the loci can guide targeted drug development such as PPARG agonists, and a new thought is provided for accurate treatment of PCOS.

The application provides a traditional Chinese medicine compound for treating polycystic ovary syndrome insulin resistance, and relates to the technical field of traditional Chinese medicine preparation. In the traditional Chinese medicine compound, gentiana scabra, and sophora flavescens are used as monarch drugs, scrophularia ningpoensis, sophora flavescens, smilax glabra, and radix rehmanniae are used as ministerial drugs, and then, humulus scandens, plantago, angelica sinensis, taraxacum, lycopus virginicus, luffa, chihkiu, and curcuma zedoary are used as auxiliary drugs. The whole prescription is used for clearing heat and drying dampness, purging fire and nourishing yin, and promoting dampness and dredging collaterals, and is suitable for treating polycystic ovary syndrome insulin resistance of the liver meridian damp-heat type.